Skip to content
Screener

Oruka Therapeutics, Inc. ORKA Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

MoonLake Immunotherapeutics logo
MoonLake ImmunotherapeuticsMLTX
-$69.99M-64.4%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$64.17M+15.9%
Alumis Inc. logo
Alumis Inc.ALMS
-$93.71M+5.4%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
$14.87M+194%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
-$74.73M-31.5%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$36.94M-77.6%

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.96B+1,120%
Enterprise value$5.91B+1,289%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:01 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001213900-26-055769
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Net loss$(31,820)$(20,999)
Other comprehensive income (loss):
Unrealized gains (losses) on marketable securities(1,026)35
Total comprehensive loss$(32,846)$(20,964)

Item 1. Financial Statements (Unaudited)

FAQ

What is Oruka Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
Oruka Therapeutics, Inc. (ORKA) reported comprehensive income (loss), net of tax, attributable to parent of -$32.85M in Q1 2026.
How has Oruka Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Oruka Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent decreased by 56.7% year-over-year, from -$20.96M to -$32.85M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
Represents the total change in equity during the period from non-owner sources, including net income and other comprehensive income items. It provides a holistic view of the company's financial performance beyond standard net income.

Ask your AI about Oruka Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude